Tracking Blood Protein Shifts Over Two Years Improves Liver Cancer Risk Detection In Cirrhosis Patients
Serial biomarker testing adds prognostic value beyond a single snapshot, offering a path to refine surveillance for vulnerable individuals.
Serial monitoring of a specific blood protein profile over a two-year window can help detect changing liver cancer risks in patients with severe scarring, according to a recent analysis of patient records from 1328 participants across multiple medical centers.
Patients living with cirrhosis face varying annual risks of developing liver cancer, known as hepatocellular carcinoma. While doctors often rely on one-time snapshot assessments to gauge this risk, a team led by researchers at the University of Texas Southwestern Medical Center explored whether tracking biomarker changes over time provides a clearer picture of who will develop tumors.
How Did Tracking Protein Signatures Over Time Reveal Changing Cancer Risks?
The study evaluated a blood-based panel called the Prognostic Liver Secretome signature, abbreviated as PLSec, alongside clinical variables in a nested case-control design. The research team examined paired serum samples from 31 patients who later developed liver cancer and 93 control participants over a 1-year period, alongside 25 cancer-developing cases and 75 controls over a 2-year period. These samples originated from the multi-center prospective National Cancer Institute HCC Early Detection Strategy cohort, which is designed to validate early detection methods.
Initial PLSec scores were higher in patients who eventually developed cancer compared to those who did not. More importantly, the change in PLSec scores from baseline to year two showed a distinct rightward shift and a statistically significant difference between the two groups. Detailed findings from this investigation were published in Hepatology Communications.
Does Serial Biomarker Testing Improve Upon Traditional Single-Time Assessments?
Statistical evaluations showed that the two-year change in the biomarker score, termed delta-PLSec-Y2, yielded an area under the receiver operating characteristic curve of 0.65. In multivariable logistic regression models, this two-year change remained significantly associated with future cancer risk even after adjusting for potential confounding demographic factors such as age and sex.
When the investigators added the two-year biomarker change to an established baseline risk prediction score known as PAaM, the statistical model fit improved. Specifically, adding the longitudinal change decreased the Akaike information criterion, a standard measure of model quality, from 58.1 to 56.8. This indicates that tracking how a patient’s protein profile shifts over twenty-four months offers complementary prognostic value that a single cross-sectional blood test misses.
What Are the Key Limitations of This Two-Year Screening Approach?
Despite these promising associations, the study authors noted several important limitations. The sample size in the matched case-control subsets was relatively small, and the study population had notable etiologic heterogeneity, which may affect the precision of the estimated odds ratios. Furthermore, the two-year follow-up window might be too brief to capture the full spectrum of biomarker shifts driven by varying underlying diseases, such as metabolic dysfunction-associated steatotic liver disease or hepatitis C virus infections.
The research team also pointed out that certain patient populations, such as individuals with chronic hepatitis B infections or Asian demographics, were underrepresented in this United States-based cohort. Consequently, these findings require independent validation in larger, more diverse prospective cohorts before clinicians can establish optimal re-testing frequencies for routine practice.
The research was published in Hepatology communications on November 19, 2026.
This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.
Last reviewed on .
Article history
- Latest version
Reference(s)
- Suzuki, Hiroyuki., et al. “Longitudinal changes in a blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in cirrhosis.” Hepatology Communications, vol. 10, no. 12, December 1, 2026 Ovid Technologies (Wolters Kluwer Health), doi: 10.1097/HC9.0000000000001081. <https://doi.org/10.1097/HC9.0000000000001081>.
Cite this page:
- Posted by Faisal Qureshi